Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 14/20 | 0.81 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441790 | 0.90 | HDAC8 (1.00) | HDAC8HDAC6HDAC1HDAC7HDAC9 | |
| SCHEMBL9452869 | 0.85 | HDAC8 (0.68) | HDAC8HDAC6TBXAS1TBXA2R | |
| SCHEMBL9833792 | 0.80 | HDAC8 (0.65) | HDAC8HDAC6TBXAS1TBXA2R | |
| SCHEMBL9452893 | 0.79 | HDAC8 (0.64) | HDAC8HDAC6TBXAS1TBXA2R | |
| SCHEMBL354885 | 0.78 | HDAC8 (0.80) | HDAC8HDAC6 | |
| SCHEMBL10405754 | 0.78 | APOB (0.57) | HDAC8HDAC6TBXA2R | |
| SCHEMBL355191 | 0.77 | HDAC8 (0.59) | HDAC8HDAC6 | |
| SCHEMBL9203595 | 0.76 | TBXAS1 (0.70) | HDAC8HDAC6TBXAS1TBXA2R | |
| SCHEMBL1282031 | 0.76 | HDAC8 (0.56) | HDAC8 | |
| Bicarbonate SCHEMBL15226047 | 0.75 | NAMPT (0.57) | HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2613775-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-17 | — | — | EP | claimed |
| WO-2012031993-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | claimed |